Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5)

사용자 리뷰
제품 번호/규격
가격
Availability
수량
AA9-Y2142-100ug
$400.00
In Stock - Delivery in 2-3 business days
AA9-Y2142-1mg
$2770.00
In Stock - Delivery in 2-3 weeks
총 항목 수 제품 금액$ 0

제품 세부정보

  • Source

    Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.

  • Antibody Type

    Hybridoma Monoclonal

  • Clone

    28B9C5

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Immunogen

    AAV9

  • Application

    Application
    Recommended Usage
    ELISA
    0.2-2 μg/mL
  • Cross Verification

    This product can specially react with AAV9.
    No reactivity to AAV1/ AAV2/ AAV3/ AAV5/ AAV6/ AAV8.

  • Purification

    Protein A purified / Protein G purified.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Liquid

  • Formulation

    Supplied a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • Bioactivity-ELISA

     AAV9 ELISA

    Immobilized AAV9 at 1E+10capsids/ml (100 μl/well) can bind Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) (Cat. No. AA9-Y2142) with a linear range of 0.50-30ng/mL (QC tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

AAV9 (Adeno-Associated Virus Serotype 9) is a highly efficient and safe gene therapy vector belonging to the Parvoviridae family. It is characterized by broad tissue tropism, enabling efficient transduction of the heart, liver, skeletal muscle, central nervous system (with the ability to cross the blood-brain barrier), and retina, among others. Compared to other serotypes, AAV9 exhibits stronger systemic diffusion capacity and lower immunogenicity, reducing the risk of host immune rejection. Its single-stranded DNA genome (~4.7 kb) allows long-term stable expression of transgenes but has a limited packaging capacity (≤5 kb).
AAV9 has been utilized in clinical trials for various diseases, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial hypercholesterolemia.

프론티어 진행

 
연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호